Fortress Biotech (FBIO) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		50,332,002

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 134,037	$ 88,294
Accounts receivable	1,368	1,830
Cash deposits with clearing organizations	1,030	1,030
Receivables from broker-dealers and clearing organizations	2,858	3,357
Forgivable loans receivable	1,528	1,712
Securities owned, at fair value	1,206	2,357
Inventory	204	203
Other receivables - related party	1,034	1,790
Prepaid expenses and other current assets	8,542	9,061
Total current assets	151,807	109,634
Property and equipment, net	7,386	7,376
Restricted cash	15,860	15,860
Long-term investments, at fair value	746	1,414
Intangible assets	17,077	17,408
Goodwill	18,645	18,645
Other assets	390	394
Total assets	211,911	170,731
Current liabilities
Accounts payable and accrued expenses	24,864	23,871
Accrued commissions and payroll payable	10,190	11,940
Contingent consideration payable	623	424
Deferred clearing and marketing credits	943	995
Securities sold, not yet purchased, at fair value	1	298
Warrants issuable - National	10,096	14,359
Interest payable	89	88
Interest payable - related party	96	77
Notes payable, short-term	2,105	1,000
Subsidiary convertible note, short-term, at fair value	3,147	1,031
Contingently issuable liabilities	0	1,682
Derivative warrant liability	402	481
Other current liabilities	244	319
Total current liabilities	52,800	56,565
Notes payable, long-term (net of debt discount of $2,549 and $2,009 at March 31, 2017 and December 31, 2016, respectively)	26,137	22,528
Subsidiary convertible note, long-term, at fair value	1,637	3,656
Other long-term liabilities	5,020	5,014
Total liabilities	85,594	87,763
Commitments and contingencies
Stockholders' equity
Common Stock, $.001 par value, 100,000,000 shares authorized, 50,319,919 and 48,932,023 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	50	49
Additional paid-in-capital	304,929	283,697
Accumulated deficit	(257,233)	(245,251)
Total stockholders' equity attributed to the Company	47,746	38,495
Non-controlling interests	78,571	44,473
Total stockholders' equity	126,317	82,968
Total liabilities and stockholders' equity	211,911	170,731
Series C Convertible Preferred Stock [Member]
Stockholders' equity
Convertible Preferred stock, $.001 par value, 129,767 Series C shares authorized, 0 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Discount	$ 2,549	$ 2,009
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	50,319,919	48,932,023
Common Stock, shares outstanding	50,319,919	48,932,023
Series C Convertible Preferred Stock [Member]
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	129,767	129,767
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue
Revenues	$ 44,682
Net revenue	44,682	$ 660
Operating expenses
Cost of goods sold - product revenue	469
Research and development	8,404
Research and development - licenses acquired	1,294	83
General and administrative	7,985
Total operating expenses	62,259	15,751
Loss from operations	(17,577)	(15,091)
Other income (expenses)
Interest income	136	75
Interest expense and financing fee	(698)	(620)
Change in fair value of derivative liabilities	4,342	(89)
Change in fair value of subsidiary convertible note	(97)	0
Change in fair value of investments	(668)	(918)
Total other income (expenses)	3,015	(1,552)
Net loss	(14,562)	(16,643)
Net loss attributable to non-controlling interests	(2,580)	(4,438)
Net loss attributable to common stockholders	$ (11,982)	$ (12,205)
Basic and diluted net loss per common share	$ (0.30)	$ (0.31)
Weighted average common shares outstanding—basic and diluted	40,357,711	39,658,188
Parent Company [Member]
Revenue
Product revenue, net	$ 2,085	$ 383
Revenue - from a related party	693	277
Revenues	2,778	660
Operating expenses
Cost of goods sold - product revenue	469	0
Research and development	7,110	7,736
Research and development - licenses acquired	1,294	83
General and administrative	10,252	7,932
Total operating expenses	19,125	15,751
National Holdings Corporation [Member]
Revenue
Commissions	24,506	0
Net dealer inventory gains	2,511	0
Investment banking	7,061	0
Investment advisory	3,385	0
Interest and dividends	716	0
Transfer fees and clearing services	2,498	0
Tax preparation and accounting	856	0
Other	371	0
Revenues	41,904	0
Operating expenses
Commissions, compensation and fees	37,258	0
Clearing fees	738	0
Communications	722	0
Occupancy	1,008	0
Licenses and registration	405	0
Professional fees	1,263	0
Interest	4	0
Depreciation and amortization	506	0
Other administrative expenses	1,230	0
Total operating expenses	$ 43,134	$ 0

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders’ Equity - 3 months ended Mar. 31, 2017 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit	Non-Controlling Interests [Member]
Balance at Dec. 31, 2016	$ 82,968	$ 49	$ 283,697	$ (245,251)	$ 44,473
Balance (in shares) at Dec. 31, 2016		48,932,023
Stock-based compensation expense	2,929	$ 0	2,929	0	0
Issuance of restricted stock	0	$ 1	(1)	0	0
Issuance of restricted stock (in shares)		1,387,896
Issuance of subsidiaries' common shares for license expenses	1,712	$ 0	1,712	0	0
Subsidiary's offering, net	52,906	0	52,906	0	0
Debt discount related to Opus Credit Facility	158	0	158	0	0
Issuance of warrants in conjunction with NSC debt	206	0	206	0	0
Non-controlling interest in subsidiaries	0	0	(36,678)	0	36,678
Net loss attributable to non-controlling interest	(2,580)	0	0	0	(2,580)
Net loss attributable to common stockholders	(11,982)	0	0	(11,982)	0
Balance at Mar. 31, 2017	$ 126,317	$ 50	$ 304,929	$ (257,233)	$ 78,571
Balance (in shares) at Mar. 31, 2017		50,319,919

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash Flows from Operating Activities:
Net Loss	$ (14,562)	$ (16,643)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization expense	682	4
Amortization of debt discount	246	369
Amortization of product revenue license fee	133	0
Amortization of forgivable loans to registered representatives	201	0
Amortization of deferred clearing credit	(52)	0
Stock-based compensation expense	2,929	2,866
Recovery for doubtful accounts	(115)	0
Issuance of subsidiaries' common shares for license expenses	30	48
Financing fees on subsidiaries' Convertible Note, at fair value	4	0
Change in fair value of investments	668	918
Change in fair value of derivative liabilities	(4,342)	89
Change in fair value of subsidiary convertible note	97	0
Change in fair value of contingent consideration payable	7
Research and development-licenses acquired, expense	1,265	35
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable	462	0
Receivables from broker-dealers and clearing organizations	499	0
Forgivable loans receivable	(17)	0
Securities owned, at fair value	1,151	0
Inventory	(1)	0
Other receivables - related party	756	(1,158)
Prepaid expenses and other current assets	635	(166)
Accounts payable and accrued expenses	(1,882)	169
Securities sold, but not yet purchased, at fair value	(297)	0
Interest payable	2	0
Interest payable - related party	30	0
Other long-term liabilities	(4)	1,832
Net cash used in operating activities	(11,475)	(11,637)
Cash Flows from Investing Activities:
Purchase of research and development licenses	(665)	(35)
Purchase of property and equipment	(261)	(2,293)
Purchase of license	0	(200)
Security deposits refund	3	0
Acquisition of business - National	(19)	0
Investment in Origo Acquisition Corp.	0	(175)
Net cash used in investing activities	(942)	(2,703)
Cash Flows from Financing Activities:
Proceeds from subsidiary's offering	55,904	570
Payment of costs related to subsidiary's offering	(2,998)	(205)
Payment of NSC Note	0	(2,792)
Proceeds from 2017 Subordinated Note Financing	3,254	0
Proceeds from Opus Credit Facility	2,000	0
Net cash provided by (used in) financing activities	58,160	(2,427)
Net increase (decrease) in cash and cash equivalents	45,743	(16,767)
Cash and cash equivalents at beginning of period	88,294	98,182
Cash and cash equivalents at end of period	134,037	81,415
Supplemental disclosure of cash flow information:
Cash paid for interest	58	77
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	1	2
Issuance of warrants to National as placement agent in conjunction with NSC Debt	206	0
Debt discount related to Opus Credit Facility	158	0
Common shares issuable for license acquired	$ 1,682	$ 0

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also referred to herein as the “Fortress Companies.” Additionally, the Company has a controlling interest in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, herein referred to as “NHLD” or “National”). In addition to its internal development programs, the Company leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. The Company and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings (including financings facilitated by NHLD) to accelerate and provide additional funding to support their research and development programs. As of March 31, 2017, in addition to NHLD, the Company has several consolidated Fortress Companies, some of which contain product licenses, including Avenue Therapeutics, Inc. (“ Avenue Cellvation Journey JMC Coronado SO Checkpoint Mustang Helocyte Escala Caelum Cyprium National On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 22.9

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2017, from which the Company derived the balance sheet data at December 31, 2016, as well as National’s Form 10-Q, filed with the SEC on February 14, 2017, Checkpoint’s Forms 10-K and 10-K/A, filed with the SEC on March 17, 2017 and March 21, 2017, respectively, Mustang’s Form 10-K, filed with the SEC on March 31, 2017, and Avenue’s Form 10-12G/A, filed with the SEC on March 27, 2017. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium, Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte, Cellvation and Caelum. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2017. Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-0 Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business and related disclosures.

National Holdings Corporation

National Holdings Corporation	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
National Holdings Corporation	3. National Holdings Corporation On September 9, 2016, the Company, purchased approximately 56.6 0.02 3.25 On April 27, 2016, the Company entered into an Agreement and Plan of Merger with National and a wholly owned subsidiary of the Company, providing for the acquisition of National (the “Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions described therein, the Company agreed to cause its wholly owned subsidiary to commence a tender offer for all the issued and outstanding shares of National’s common stock, par value $ 0.02 3.25 7 56.6 22.9 ($ in thousands) Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626 The preliminary estimated fair values of the assets acquired and liabilities assumed will be finalized as further information is received regarding these items and analysis of this information is completed. The Company preliminarily recognized $ 18.6 Intangible assets consist of trademark and customer lists acquired in the offer under the purchase method of accounting and are recorded at preliminary fair value net of accumulated amortization since the purchase date. Useful life Trademark 10 years Customer lists 10 years Intangible assets at December 31, 2016 $ 15,991 Amortization expense (408) Intangible assets at March 31, 2017 $ 15,583 Total Nine Months Ended December 31, 2017 $ 1,242 Year Ended December 31, 2018 1,649 Year Ended December 31, 2019 1,649 Year Ended December 31, 2020 1,654 Year Ended December 31, 2021 1,649 Thereafter 7,740 Total $ 15,583 The Company reviews its finite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of a finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no indicators of impairment during the period ended March 31, 2017.

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2017
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	4. Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities At December 31, 2016, National’s receivables of $ 2.9 3.9 0.6

Forgivable Loans Receivable

Forgivable Loans Receivable	3 Months Ended
	Mar. 31, 2017
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National's operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (interest ranging up to 9 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of December 31, 2016, no allowance for doubtful accounts was required. There were no unamortized forgivable loans outstanding at December 31, 2016 attributable to registered representatives who ended their affiliation with National’s subsidiaries prior to the fulfillment of their obligation.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	6. Property and Equipment Estimated Useful March 31, December 31, Lives (in years) 2017 2016 Computer equipment 3 $ 489 $ 440 Furniture and fixtures 5 887 821 Leasehold improvements Various 5,401 5,396 Total property and equipment 6,777 6,657 Less: accumulated depreciation (621) (445) Property and equipment, net $ 6,156 $ 6,212 Fortress's depreciation expense for the three months ended March 31, 2017 and 2016, was approximately $ 176,000 4,000 December 31, Estimated Useful 2016 Lives (in years) Equipment $ 719 5 Furniture and fixtures 71 5 Leasehold improvements 298 Lesser of useful life or term of lease Capital leases (primarily composed of computer equipment) 276 5 Total property and equipment 1,364 Less: accumulated depreciation (134) Property and equipment, net $ 1,230

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Laser Device for Treatment of Migraine Headache On March 17, 2014, the Company invested $ 250,000 35 13,409,962 83 16,091,954 0.3 Origo Acquisition Corporation (formerly CB Pharma Acquisition Corporation) On December 19, 2016, Origo Acquisition Corporation (“Origo”) entered into a merger agreement (“Origo Merger Agreement”) with Aina Le’a Inc. (“Aina Le’a”), a residential and commercial real estate developer in Hawaii. On February 17, 2017, Origo sent a letter, as supplemented on February 22, 2017 (the “Termination Letter”), to Aina Le’a terminating the Origo Merger Agreement. As of March 31, 2017, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 18.4 9.83 0.18 0.11 0.7 0.5 0.3 Contingently Issuable Warrant Pursuant to the Company’s promissory note with NSC of March 2015, as amended in July 2015 (the “NSC Note”), if the Company transfers any proceeds from the NSC Note to a Fortress Company, such Fortress Company will issue to NSC Biotech Venture Fund I LLC a new promissory note on identical terms as the NSC Note and NSC Biotech Venture Fund I LLC will also receive a warrant to purchase a number of shares of such Fortress Company’s stock equal to 25% of the outstanding Fortress Company note divided by the lowest price for which the Fortress Company sells its equity in its first third party financing. The warrants issued will have a term of 10 years and an exercise price equal to the par value of the Fortress Company’s common stock and are accounted for in accordance with ASC 815, Derivatives and Hedging. Avenue classified the fair value of the contingently issuable warrants granted in connection with the transfer from Fortress of $ 3.0 March 31, 2017 Risk-free interest rate 2.40 % Expected dividend yield - Expected term in years 8.59 Expected volatility 83 % Probability of issuance of the warrant 50 % Avenue’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2017 $ 302 Change in fair value (4) Ending balance at March 31, 2017 $ 298 Avenue Warrant Liabilities On December 30, 2016, Avenue held a closing of the sale of convertible promissory notes. In the closing, WestPark Capital, Inc., the placement agent (“ WestPark WestPark Warrant 10,000 March 31, 2017 Risk-free interest rate 2.39 % Expected dividend yield - Expected term in years 9.76 Expected volatility 86 % There was no change in fair value of Avenue’s warrant liability for the three months ended March 31, 2017. Helocyte Warrant Liabilities The fair value of Helocyte’s warrant liability was measured at fair value using a Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (level 3 inputs) used in measuring Helocyte’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of March 31, 2017 is as follows: March 31, 2017 Risk-free interest rate 1.769% – 1.859 % Expected dividend yield - % Expected term in years 4.25 - 4.67 Expected volatility 70.0 % Strike price $ 0.44 Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2017 $ 167 Change in fair value of derivative liabilities (75) Ending balance at March 31, 2017 $ 92 Convertible Notes at Fair Value Helocyte’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Helocyte’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of March 31, 2017 is as follows: March 31, 2017 Risk-free interest rate 0.910% - 1.189 % Expected dividend yield - % Expected term in years 0.50 - 1.66 Expected volatility 61.7 % Helocyte Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 4,487 Change in fair value of convertible notes 93 Ending balance at March 31, 2017 $ 4,580 Avenue’s convertible debt is measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Avenue’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of March 31, 2017 is as follows: March 31, 2017 Risk-free interest rate 0.91% - 1.21 % Expected dividend yield - % Expected term in years 0.50 - 1.75 Expected volatility 61.7 % Avenue Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 200 Change in fair value of convertible notes 4 Ending balance at March 31, 2017 $ 204 Fair Value Measurement as of March 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 746 $ 746 Total $ - $ - $ 746 $ 746 Liabilities Contingently Issuable Warrants $ - $ - $ 298 $ 298 Warrant liabilities - - 104 104 Helocyte Convertible Note, at fair value - - 4,580 4,580 Avenue Convertible Note, at fair value - - 204 204 Total $ - $ - $ 5,186 $ 5,186 Fair Value Measurement as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 172 $ - $ - $ 172 Municipal bonds 930 - - 930 Restricted stock - 104 - 104 Total $ 1,102 $ 104 $ - $ 1,206 Liabilities National Securities sold, but not yet purchased at fair value Corporate stocks $ 1 $ - $ - $ 1 Warrants issuable - National 10,096 10,096 Total $ 1 $ - $ 10,096 $ 10,097 Warrants issuable - National In accordance with the Company’s Merger Agreement with National, since less than 80 3.25 As National does not have the ability to settle the warrants with unregistered shares and maintenance of an effective registration statement may be considered outside of the Company’s control, net cash settlement of the warrants is assumed. The fair value of the 5.4 43.4 December 31, 2016 Dividend yield - % Expected volatility 98.23 % Risk-free interest rate 1.93 % Life (in years) 4.7 National’s ($ in thousands) Warrants Beginning balance at October 1, 2016 $ 14,359 Change in fair value of derivative liability (4,263) Ending balance at December 31, 2016 $ 10,096 National listed the warrants on the Nasdaq Capital Market under the symbol “NHLDW” in February 2017. Helocyte Avenue Convertible Convertible Contingently Investment in Investment in Note, at fair Note, at fair Issuable Warrant ($ in thousands) Origo laser device value value Warrants liabilities Total Balance at December 31, 2016 $ 1,164 $ 250 $ 4,487 $ 200 $ 14,661 $ 179 $ 20,941 Change in fair value of investments (668) - - - - - (668) Change in fair value of convertible notes - - 93 4 - - 97 Change in fair value of derivative liabilities - - - - (4,267) (75) (4,342) Balance at March 31, 2017 $ 496 $ 250 $ 4,580 $ 204 $ 10,394 $ 104 $ 16,028 For the three months ended March 31, 2017, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Licenses Acquired

Licenses Acquired	3 Months Ended
	Mar. 31, 2017
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development 1.3 For the Three Months Ended March 31, ($ in thousands) 2017 2016 Fortress Companies: Checkpoint $ 400 $ - Helocyte - 83 Mustang 575 - Caelum 219 - Cyprium 100 - Total $ 1,294 $ 83 Checkpoint Therapeutics, Inc. Jubilant Biosys Limited In May 2016, Checkpoint entered into a license agreement with Jubilant Biosys Limited (“ Jubilant Jubilant License 0.4 In connection with the Jubilant License, Checkpoint entered into a sublicense agreement (the “Sublicense Agreement”) with TG Therapeutics, Inc. (“TGTX”), a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, with Checkpoint retaining the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and the Company’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. For the three months ended March 31, 2017, Checkpoint recognized $ 0.5 0.2 Dana-Farber Cancer Institute In connection with its license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies, while Checkpoint retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and Fortress’s Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. For the three months ended March 31, 2017 and 2016, approximately $ 28,000 17,000 Mustang Bio, Inc. License Agreement with the City of Hope In March 2015, Mustang entered into an exclusive license agreement with City of Hope (“COH”) to acquire intellectual property rights pertaining to CAR-T (the “Original License”). On February 17, 2017, Mustang and COH amended and restated the Original License by entering into three separate exclusive license agreements, one relating to CD123 (the “CD123 License”), one relating to IL-13 (the “IL-13 License”) and one relating to the spacer technology (the “Spacer License”). The total potential consideration payable to COH by Mustang under the new license agreements, in equity or cash, did not, in the aggregate, change materially from the Original License. CD123 License Pursuant to the CD123 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive milestone payments totaling approximatel 14.5 IL-13 License Pursuant to the IL-13 License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. COH is eligible to receive milestone payments totaling approximately $ 14.5 0.3 Spacer License Pursuant to the Spacer License, Mustang and COH acknowledge that an upfront fee was paid under the Original License. In addition, an annual maintenance fee will continue to apply. No royalties are due if the Spacer technology is used in conjunction with a CD123 CAR or an IL-13 CAR, and royalty payments in the low single digits are due on net sales of licensed products if the Spacer technology is used in conjunction with other intellectual property. Mustang is obligated to pay COH a percentage (in the mid-thirties) of certain revenues received in connection with a sublicense. In addition, equity grants made under the Original License were acknowledged, and the anti-dilution provisions of the Original License were carried forward. IV/ICV Agreement On February 17, 2017, Mustang entered into an exclusive license agreement (the “IV/ICV Agreement”) with COH to acquire intellectual property rights in patent applications related to the intraventricular and intracerebroventricular methods of delivering T cells that express CARs. Pursuant to the IV/ICV Agreement, Mustang paid COH an upfront fee of $ 0.1 0.1 License with University of California On March 17, 2017, Mustang entered into an exclusive license agreement with the Regents of the University of California (“UCLA License”) to acquire intellectual property rights in patent applications related to the engineered anti-prostate stem cell antigen antibodies for cancer targeting and detection. Pursuant to the UCLA Agreement, Mustang paid UCLA an upfront fee of $ 0.2 Caelum Biosciences, Inc. License Agreement with Columbia University In January 2017, Caelum entered into an exclusive license agreement with Columbia University (“Columbia”) to secure worldwide license rights to CAEL-101 (11-1F4), a chimeric fibril-reactive monoclonal antibody (mAb) being evaluated in a Phase 1a/1b study for the treatment of amyloid light chain (“AL”) amyloidosis. This transaction was accounted for as an asset acquisition pursuant to ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.2 1,050,000 10 29,000 0.028 5.5 Cyprium Therapeutics, Inc. License Agreement with the Eunice Kennedy Shriver In March 2017, Cyprium and the Eunice Kennedy Shriver NICHD NIH Business Combinations (Topic 805): Clarifying the Definition of a Business, . 0.1

Sponsored Research Agreements

Sponsored Research Agreements	3 Months Ended
	Mar. 31, 2017
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Sponsored Research Agreements Checkpoint Therapeutics, Inc. In connection with its license agreement with NeuPharma, Inc. (“NeuPharma”), Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX, a related party, agreed to assume all costs associated with this Sponsored Research Agreement and paid Checkpoint for all amounts previously paid by the Company. For the three months ended March 31, 2017 and 2016, approximately $ 0.2 0.3 Helocyte, Inc. In March 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its PepVax immunotherapy for CMV control in allogeneic stem cell transplant recipients (“ PepVax Research Agreement NCI In February 2016, Helocyte entered into an Investigator-Initiated Clinical Research Support Agreement, as amended, with the COH, to support a Phase 2 clinical study of its Triplex immunotherapy for CMV control in allogeneic stem cell transplant recipients (“ Triplex Research Agreement For the three months ended March 31, 2017 and 2016, Helocyte incurred expense of $ 0.5 1.0 0.2 1.0 Mustang Bio, Inc. In connection with Mustang’s license with COH for the development of CAR-T, Mustang entered into a Sponsored Research Agreement in which Mustang will fund continued research in the amount of $ 2.0 0.5 0.5 On February 17, 2017, Mustang entered into a Clinical Research Support Agreement for CD123. Pursuant to the terms of this agreement Mustang made an upfront payment of $ 19,450 0.1 0.2 19,450 Also on February 17, 2017, Mustang entered into a Clinical Research Support Agreement for IL-13. Pursuant to the terms of this agreement Mustang made an upfront payment of $ 9,238 0.1 0.2 9,238

Intangibles, net

Intangibles, net	3 Months Ended
	Mar. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, net	10. Intangibles, net Journey Medical Corporation Pursuant to the terms of Journey’s license agreements for its branded products, Journey made upfront payments totaling $ 1.6 0.1

Debt and Interest

Debt and Interest	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt and Interest	11. Debt and Interest Debt March 31, December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25% Feb - 2018 NSC Note 3,608 3,608 8.00% Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00% March - 2020 Opus Credit Facility 9,000 7,000 12.00% Sep - 2018 Helocyte Convertible Note, at fair value 1,054 1,031 5.00% - 8.00% December 2017 Helocyte Convertible Note, at fair value 2,093 2,051 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,011 991 5.00% - 8.00% April - 2018 Helocyte Convertible Note, at fair value 422 414 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value 204 200 5.00% - 8.00% June - 2018 Total notes payable 35,575 30,224 Less: Discount on notes payable 2,549 2,009 Total notes payable, net $ 33,026 $ 28,215 IDB Note On February 13, 2014, the Company executed a secured promissory note in favor of Israel Discount Bank of New York (“IDB”) in the amount of $ 15.0 14.9 15.0 2017 Subordinated Note Financing On March 31, 2017, the Company entered into Note Purchase Agreements (the “ Purchase Agreements NAM Biotech Fund NAM Special Situations Fund Notes 2017 Subordinated Note Financing 3.25 8 7 Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion. 3.0 40.0 50.0 National Securities Corporation (“ NSC NAM Placement Agency Agreement Placement Agency Agreements 10 10 Placement Agent Warrants In connection with the initial closing of the 2017 Subordinated Note Financing, NSC received a cash fee of $ 325,400 87,946 0.2 Opus Credit Facility As of March 31, 2017, the Company had $ 9.0 1.8 Interest Expense For the Three Months Ended March 31, ($ in thousands) 2017 2016 IDB Note Interest $ 82 $ 80 Amortization of fees - 1 Total IDB Note 82 81 NSC Debt Interest 71 167 Amortization of fees 38 368 Total NSC Debt 109 535 Opus Credit Facility Interest 232 - Amortization of fees 208 - Total Opus Note 440 - LOC Fees Interest 8 4 Total LOC 8 4 Helocyte Convertible Note Interest 54 - Financing fee 1 - Total Helocyte Convertible Note 55 - Avenue Convertible Note Financing fee 3 - Total Helocyte Convertible Note 3 - D&O Insurance Interest 1 - Total D&O Insurance 1 - Total Interest Expense and Financing Fee $ 698 $ 620

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	12. Accrued Expenses and Other Long-Term Liabilities March 31, December 31, ($ in thousands) 2017 2016 Accrued expenses: Professional fees $ 1,450 $ 1,253 Salaries, bonuses and related benefits 3,532 2,846 Accrued Severance - 53 Ovamed manufacturing rights – short term component 900 900 Research and development 680 394 Dr. Falk Pharma milestone 2,684 2,634 Other 1,874 2,002 Total accrued expenses $ 11,120 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,020 5,014 Total other long-term liabilities $ 5,020 $ 5,014 December 31, 2016 Legal $ 752 Audit 263 Telecommunications 178 Data Services 235 Regulatory 623 Settlements 421 Deferred rent 123 Contingent consideration payable 623 Other 1,995 Total $ 5,213

Non-Controlling Interests

Non-Controlling Interests	3 Months Ended
	Mar. 31, 2017
Noncontrolling Interest [Abstract]
Non-Controlling Interests	13. Non-Controlling Interests As of March 31, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation Caelum National Holdings Total NCI equity share $ (842) $ (236) $ 46,581 $ 21,009 $ (543) $ (1,684) $ (153) $ (3) $ 17,022 $ 81,151 Net loss attributed to non-controlling interests (68) (4) (1,674) (2,734) (68) (323) (54) (145) 2,490 (2,580) Non-controlling interests in consolidated entities $ (910) $ (240) $ 44,907 $ 18,275 $ (611) $ (2,007) $ (207) $ (148) $ 19,512 $ 78,571 As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473 For the three months ended March 31, 2017 ($ in thousands) Avenue Coronado SO Mustang (2) Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (68) $ (4) $ (1,674) $ (2,734) $ (68) $ (323) $ (54) $ (145) $ 2,490 $ (2,580) Non-controlling ownership 10.2 % 13.0 % 52.0 % 62.4 % 7.0 % 20.0 % 22.0 % 25.5 % 43.4 % (1) – Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights. (2) – Mustang is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights. For the three months ended March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (108) $ (5) $ (70) $ (4,037) $ (121) $ (97) $ (4,438) Non-controlling ownership 11.5 % 13.0 % 10.0 % 62.7 % 8.1 % 8.3 %

Net Loss per Common Share

Net Loss per Common Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company’s common stock equivalents, including unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. For the Three Months Ended March 31, 2017 2016 Warrants to purchase Common Stock 383,453 544,835 Opus warrants to purchase Common Stock 1,860,000 - Options to purchase Common Stock 1,105,502 1,779,365 Unvested Restricted Stock 9,912,161 7,922,021 Unvested Restricted Stock Units 1,249,232 885,083 Total 14,510,348 11,131,304

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	15. Stockholders’ Equity Stock-based Compensation excluding National As of March 31, 2017, the Company had four equity compensation plans: the Fortress Biotech, Inc. 2007 Stock Incentive Plan, the Fortress Biotech, Inc. 2013 Stock Incentive Plan, as amended, the Fortress Biotech, Inc. 2012 Employee Stock Purchase Plan and the Fortress Biotech, Inc. Long Term Incentive Plan. For the Three Months Ended March 31, ($ in thousands) 2017 2016 Employee awards $ 1,830 $ 1,584 Non-employee awards 13 3 Fortress Companies (1) 1,086 1,279 Total stock-based compensation expense $ 2,929 $ 2,866 (1) Consists of approximately $ 5,000 1.0 46,000 47,000 8,000 Consists of approximately $ 9,000 1.1 0.2 For the three months ended March 31, 2017 and 2016, approximately $ 0.8 1.3 2.1 1.6 Weighted average Weighted Total weighted remaining average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 No activity - - - - Options vested and expected to vest at March 31, 2017 1,130,501 $ 3.73 $ 1,216,285 4.69 Options vested and exercisable 1,105,501 $ 3.71 $ 1,216,285 4.66 As of March 31, 2017 and 2016, the Company had unrecognized stock-based compensation expense related to options of nil and $ 62,000 0.1 Weighted average Number of shares grant price Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 215,000 3.61 Restricted stock units vested (41,250) 3.54 Unvested balance at March 31, 2017 11,379,908 $ 2.53 As of March 31, 2017, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $ 3.4 0.8 2.8 3.5 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 As of March 31, 2017, 177,919 22,081 35,000 27,000 Warrants Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 167,946 3.37 - 4.96 Outstanding as of March 31, 2017 2,431,399 $ 3.60 $ 209,800 2.37 Exercisable as of March 31, 2017 471,399 $ 6.08 $ 139,800 1.98 Long-Term Incentive Program (“LTIP”) On January 1, 2017, the Compensation Committee granted 552,698 100.0 1.5 0.1 8.3 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint has a long-term incentive plan under which it has issued grants to both employees and non-employees. For the three months ended March 31, 2017 and 2016, Checkpoint re-measured its non-employee grant and recorded expense of approximately $ 0.4 0.8 Certain Checkpoint employees and directors also have been awarded restricted stock under Checkpoint’s 2015 Incentive Plan. Checkpoint recorded stock-based compensation expense of $ 0.5 0.3 Checkpoint recorded approximately $ 0.1 Avenue Therapeutics, Inc. For the three months ended March 31, 2017 and 2016, Avenue recorded approximately $ 2,000 5,000 2,000 5,000 Journey Medical Corporation During the quarter ended March 31, 2017, JMC granted option awards to numerous sales employees exercisable for 290,000 The fair value of stock options granted was determined on the grant date using assumptions for risk free interest rate, the expected term, expected volatility, and expected dividend yield. The stock price was determined utilizing a discounted cash flow model to determine the weighted market value of invested capital. JMC does not expect to pay dividends in the foreseeable future. As a result, the expected dividend yield is 0 Staff Accounting Bulletin No. 110 for “plain vanilla” options. JMC obtained the risk-free interest rate from publicly available data published by the Federal Reserve. The volatility rate was computed based on a comparison of average volatility rates of similar companies. March 31, 2017 Risk-free interest rate 1.93% - 2.22 % Expected dividend yield - % Expected term in years 5.38 - 6.98 % Expected volatility 103.98% - 105.95 % During the three months ended March 31, 2017 and 2016, stock-based compensation associated with the amortization of stock option expense was approximately $ 38,000 0.1 8,000 35,000 Helocyte, Inc. For the three months ended March 31, 2017 and 2016, Helocyte re-measured its non-employee grants and recorded expense of approximately $ 37,000 62 For the three months ended March 31, 2017 and 2016, the Company recorded approximately $ 10,000 500 Cellvation, Inc. For the three months ended March 31, 2017, Cellvation recorded expenses for non-employee grants of approximately $ 3,000 For the three months ended March 31, 2017, Cellvation recorded approximately $ 5,000 Capital Raise Mustang In September 2016, Mustang entered into a Placement Agent Agreement with NSC relating to Mustang’s offering of shares of common stock in a private placement. Pursuant to the Placement Agent Agreement, Mustang agreed to pay NSC a cash fee of 10.0 10,000 2,500 8.50 65,000 On January 31, 2017, Mustang held a sixth closing of its private placement for gross proceeds of $ 55.5 8,536,774 2,134,193 5.5 853,677 10 On March 31, 2017, Mustang closed an additional private placement with substantially similar terms as the offering described above resulting in gross proceeds of $ 0.4 64,000 16,000 42,000 10 6,400 10 Pursuant to the Founders Agreement (see note 17), Mustang issued 215,019 2.5 1.2 As of March 31, 2017, the Company determined that the warrants still did not meet the definition of a derivative and continued to qualify for equity recognition.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance to address such claims. Pursuant to agreements with clinical trial sites, the Company provides indemnification to such sites in certain conditions. Legal Proceedings - Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. Litigation and Regulatory Matters - National National and its subsidiaries are defendants or respondents in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its registered representatives that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where National believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect National’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Note	17. Related Party Transactions Shared Services Agreement with TGTX TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended March 31, 2017 and 2016, the Company invoiced TGTX $ 0.2 0.1 Desk Space Agreements with TGTX and OPPM In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), as of March 31, 2017, the Company had paid $ 0.6 57,000 0.3 0.1 54,000 12,000 Opus Credit Facility In September 2016, the Company and Opus Point Health Innovations Fund (“OPHIF”) entered into a Credit Facility Agreement (the “Opus Credit Facility”). Fortress’s Chairman, President and Chief Executive Officer (Lindsay A. Rosenwald) and Fortress’s Executive Vice President, Strategic Development (Michael Weiss), are Co-Portfolio Managers and Partners of OPPM, an affiliate of OPHIF. As such, all of the disinterested directors of Fortress’s board of directors approved the terms of the Opus Credit Facility and related agreements (see Note 11). 2017 Subordinated Note Financing On March 17, 2017, the Company and National Securities Corporation (“ NSC 56.6 10 10 For the three months ended March 31, 2017, NSC earned a placement agent fee of $ 0.3 87,946 Founders Agreements The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2016, filed with the SEC on March 16, 2017. The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidaries’ certificates of incorporation. PIK Dividend as a % of fully diluted outstanding Class of Stock Fortress Company Effective Date (1) capitalization Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock (1) – Represents the effective date of each subsidiary’s Founders Agreement. While certain Founders Agreements may have been amended and restated subsequently, as described in the Company’s Form 10-K for the year ended December 31, 2016 filed with the SEC on March 16, 2017, each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) – Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5 Management Services Agreements The Company has entered in Management Services Agreements (the “MSAs”) with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2016, filed with the SEC on March 16, 2017. ($ in thousands) Fortress Annual MSA Fee Company Effective Date R&D G&A (Income)/Expense Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Fortress (1,750) (1,750) (3,500) Consolidated (Income)/Expense $ - $ - $ - Chord Advisors, LLC In May 2015, the Company entered into a full service consulting agreement with Chord Advisors, LLC (“Chord”) to provide advisory accounting services. Under the terms of the agreement, the Company pays Chord $ 10,000 5,000 7,500 28,000 National As of March 31, 2017, the Company owns approximately 56.6 Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM which owns approximately 4.6

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	3 Months Ended
	Mar. 31, 2017
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	18. Net Capital Requirements of Broker-Dealer Subsidiaries National Securities is subject to the SEC's Uniform Net Capital Rule (Rule 15c3-1) (the "Rule"), which, among other things, requires the maintenance of minimum net capital. At December 31, 2016, National Securities had net capital of $8,562,434 which was $8,312,434 in excess of its required net capital of $250,000. National Securities is exempt from the provisions of the SEC's Rule 15c3-3 since it is an introducing broker-dealer that clears all transactions on a fully disclosed basis and promptly transmits all customer funds and securities to clearing brokers. vFinance Investments is also subject to the Rule, which, among other things, requires the maintenance of minimum net capital and requires that the ratio of aggregate indebtedness to net capital, both as defined, shall not exceed 15 1 Advances, dividend payments and other equity withdrawals from the Company's broker-dealer subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2017
Risks and Uncertainties [Abstract]
Off Balance Sheet Risk and Concentrations of Credit Risk	19. Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Information	20. Segment Information Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended March 31, 2017 Sales Development National Consolidated Net Revenue $ 2,085 $ 693 $ 41,904 $ 44,682 Direct cost of goods (469) - - (469) Sales and marketing costs (2,267) - - (2,267) Research and development - (8,404) - (8,404) General and administrative (319) (7,666) - (7,985) National Expenses - - (43,134) (43,134) Segment loss from operations $ (970) $ (15,377) $ (1,230) $ (17,577) Segment assets $ 4,039 $ 159,175 $ 48,697 $ 211,911 Significant Customers For the three months ended March 31, 2017, two of the Company’s customers each accounted for more than 10.0% of its total gross revenue in the amount of $ 0.8 0.5 At March 31, 2017, two of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 0.8 0.5 At December 31, 2016, two of the Company’s customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 1.1 0.5 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint, which is classified as related party revenue.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events 2017 Subordinated Note Financing Second Closing On May 1, 2017, the Company held a second closing of the 2017 Subordinated Note Financing and received gross proceeds of $8.55 million, before expenses. NSC received a placement agent fee of approximately $0.9 million in the second closing and warrants to purchase 234,438 shares of the Company’s common stock at an exercise price of $3.65 per share.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year for each of the Company, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2017, from which the Company derived the balance sheet data at December 31, 2016, as well as National’s Form 10-Q, filed with the SEC on February 14, 2017, Checkpoint’s Forms 10-K and 10-K/A, filed with the SEC on March 17, 2017 and March 21, 2017, respectively, Mustang’s Form 10-K, filed with the SEC on March 31, 2017, and Avenue’s Form 10-12G/A, filed with the SEC on March 27, 2017. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: NHLD, Innmune Limited, Coronado SO, Cyprium, Escala, JMC, CB Securities Corporation, Avenue, Checkpoint, Mustang, Helocyte, Cellvation and Caelum. All intercompany balances and transactions have been eliminated. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2017.
Recently Issued Accounting Standards	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-0 Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Liabilities In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash In January 2017, the FASB issued an ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business and related disclosures.

National Holdings Corporation (

National Holdings Corporation (Tables)	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Schedule fair value of assets acquired and liabilities assumed at the date of the acquisition	The following table summarizes the preliminary fair value of assets acquired and liabilities assumed at the date of the acquisition: ($ in thousands) Assets Cash and cash equivalents $ 27,498 Accounts receivable 4,889 Cash deposits with clearing organizations 1,030 Receivable from brokers, dealers and clearing agencies 1,607 Securities owned, at fair value 2,178 Prepaid expenses and other current assets 1,985 Property and equipment 1,132 Restricted cash 353 Intangible assets - trademark 3,000 Intangible assets - customer list 13,500 Goodwill 18,645 Total assets 75,817 Liabilities Accrued compensation payable $ 14,029 Accounts payable and accrued expenses 6,079 Deferred clearing and marketing credits 1,007 Warrants issuable 13,406 Other current liabilities 707 Total liabilities assumed 35,228 Non-controlling interests 17,717 Net assets acquired $ 22,872 Cash and cash equivalents from National $ 27,498 Cash to NHLD Shareholders (Tender Offer) 22,872 Net cash acquired in acquisition of National $ 4,626
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Amortization is calculated using the straight-line and accelerated methods over the following estimated useful lives: Useful life Trademark 10 years Customer lists 10 years
Schedule of Finite-Lived Intangible Assets	The gross carrying amounts related to acquired intangible assets as of March 31, 2017 are as follows ($ in thousands): Intangible assets at December 31, 2016 $ 15,991 Amortization expense (408) Intangible assets at March 31, 2017 $ 15,583
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The future amortization of these intangible assets is as follows ($ in thousands): Total Nine Months Ended December 31, 2017 $ 1,242 Year Ended December 31, 2018 1,649 Year Ended December 31, 2019 1,649 Year Ended December 31, 2020 1,654 Year Ended December 31, 2021 1,649 Thereafter 7,740 Total $ 15,583

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	Fortress's property and equipment, exclusive of National's property and equipment, consisted of the following ($ in thousands): Estimated Useful March 31, December 31, Lives (in years) 2017 2016 Computer equipment 3 $ 489 $ 440 Furniture and fixtures 5 887 821 Leasehold improvements Various 5,401 5,396 Total property and equipment 6,777 6,657 Less: accumulated depreciation (621) (445) Property and equipment, net $ 6,156 $ 6,212
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	National's property and equipment as of December 31, 2016 consisted of the following ($ in thousands): December 31, Estimated Useful 2016 Lives (in years) Equipment $ 719 5 Furniture and fixtures 71 5 Leasehold improvements 298 Lesser of useful life or term of lease Capital leases (primarily composed of computer equipment) 276 5 Total property and equipment 1,364 Less: accumulated depreciation (134) Property and equipment, net $ 1,230

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue’s Contingently Issuable ($ in thousands) Warrants Beginning balance at January 1, 2017 $ 302 Change in fair value (4) Ending balance at March 31, 2017 $ 298
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables classify the fair value hierarchy of Fortress's financial instruments, exclusive of National's financial instruments, measured at fair value as of March 31, 2017 and December 31, 2016: Fair Value Measurement as of March 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 746 $ 746 Total $ - $ - $ 746 $ 746 Liabilities Contingently Issuable Warrants $ - $ - $ 298 $ 298 Warrant liabilities - - 104 104 Helocyte Convertible Note, at fair value - - 4,580 4,580 Avenue Convertible Note, at fair value - - 204 204 Total $ - $ - $ 5,186 $ 5,186
Schedule of changes in fair value of financial instruments	Helocyte Avenue Convertible Convertible Contingently Investment in Investment in Note, at fair Note, at fair Issuable Warrant ($ in thousands) Origo laser device value value Warrants liabilities Total Balance at December 31, 2016 $ 1,164 $ 250 $ 4,487 $ 200 $ 14,661 $ 179 $ 20,941 Change in fair value of investments (668) - - - - - (668) Change in fair value of convertible notes - - 93 4 - - 97 Change in fair value of derivative liabilities - - - - (4,267) (75) (4,342) Balance at March 31, 2017 $ 496 $ 250 $ 4,580 $ 204 $ 10,394 $ 104 $ 16,028
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	December 31, 2016 Dividend yield - % Expected volatility 98.23 % Risk-free interest rate 1.93 % Life (in years) 4.7
Fair Value for Derivative Contingently Issuable Warrant Liabilities	National’s ($ in thousands) Warrants Beginning balance at October 1, 2016 $ 14,359 Change in fair value of derivative liability (4,263) Ending balance at December 31, 2016 $ 10,096
Avenue [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	The fair value of Avenue’s contingently issuable warrants was determined by applying management’s estimate of the probability of issuance of the contingently issuable warrants together with an option pricing model, with the following key assumptions: March 31, 2017 Risk-free interest rate 2.40 % Expected dividend yield - Expected term in years 8.59 Expected volatility 83 % Probability of issuance of the warrant 50 %
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	March 31, 2017 Risk-free interest rate 0.91% - 1.21 % Expected dividend yield - % Expected term in years 0.50 - 1.75 Expected volatility 61.7 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Avenue Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 200 Change in fair value of convertible notes 4 Ending balance at March 31, 2017 $ 204
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	March 31, 2017 Risk-free interest rate 2.39 % Expected dividend yield - Expected term in years 9.76 Expected volatility 86 %
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	March 31, 2017 Risk-free interest rate 0.910% - 1.189 % Expected dividend yield - % Expected term in years 0.50 - 1.66 Expected volatility 61.7 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Helocyte Convertible Note, at fair ($ in thousands) value Beginning balance at January 1, 2017 $ 4,487 Change in fair value of convertible notes 93 Ending balance at March 31, 2017 $ 4,580
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	March 31, 2017 Risk-free interest rate 1.769% – 1.859 % Expected dividend yield - % Expected term in years 4.25 - 4.67 Expected volatility 70.0 % Strike price $ 0.44
Fair Value for Derivative Contingently Issuable Warrant Liabilities	Fair Value of Derivative Warrant ($ in thousands) Liability Beginning balance at January 1, 2017 $ 167 Change in fair value of derivative liabilities (75) Ending balance at March 31, 2017 $ 92
National Holdings Corporation [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table shows the fair values hierarchy of National's financial instruments measured at fair value on a recurring basis on the Condensed Consolidated Balance Sheets as of December 31, 2016: Fair Value Measurement as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 172 $ - $ - $ 172 Municipal bonds 930 - - 930 Restricted stock - 104 - 104 Total $ 1,102 $ 104 $ - $ 1,206 Liabilities National Securities sold, but not yet purchased at fair value Corporate stocks $ 1 $ - $ - $ 1 Warrants issuable - National 10,096 10,096 Total $ 1 $ - $ 10,096 $ 10,097

Licenses Acquired (Tables)

Licenses Acquired (Tables)	3 Months Ended
	Mar. 31, 2017
Research and Development [Abstract]
Research and Development Arrangement, Contract to Perform for Others	1.3 For the Three Months Ended March 31, ($ in thousands) 2017 2016 Fortress Companies: Checkpoint $ 400 $ - Helocyte - 83 Mustang 575 - Caelum 219 - Cyprium 100 - Total $ 1,294 $ 83

Debt and Interest (Tables)

Debt and Interest (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Total debt consists of the following as of March 31, 2017 and December 31, 2016: March 31, December 31, ($ in thousands) 2017 2016 Interest rate Maturity IDB Note $ 14,929 $ 14,929 2.25% Feb - 2018 NSC Note 3,608 3,608 8.00% Sep - 2018 2017 Subordinated Note Financing 3,254 - 8.00% March - 2020 Opus Credit Facility 9,000 7,000 12.00% Sep - 2018 Helocyte Convertible Note, at fair value 1,054 1,031 5.00% - 8.00% December 2017 Helocyte Convertible Note, at fair value 2,093 2,051 5.00% - 8.00% March - 2018 Helocyte Convertible Note, at fair value 1,011 991 5.00% - 8.00% April - 2018 Helocyte Convertible Note, at fair value 422 414 5.00% - 8.00% May - 2018 Avenue Convertible Note, at fair value 204 200 5.00% - 8.00% June - 2018 Total notes payable 35,575 30,224 Less: Discount on notes payable 2,549 2,009 Total notes payable, net $ 33,026 $ 28,215
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: For the Three Months Ended March 31, ($ in thousands) 2017 2016 IDB Note Interest $ 82 $ 80 Amortization of fees - 1 Total IDB Note 82 81 NSC Debt Interest 71 167 Amortization of fees 38 368 Total NSC Debt 109 535 Opus Credit Facility Interest 232 - Amortization of fees 208 - Total Opus Note 440 - LOC Fees Interest 8 4 Total LOC 8 4 Helocyte Convertible Note Interest 54 - Financing fee 1 - Total Helocyte Convertible Note 55 - Avenue Convertible Note Financing fee 3 - Total Helocyte Convertible Note 3 - D&O Insurance Interest 1 - Total D&O Insurance 1 - Total Interest Expense and Financing Fee $ 698 $ 620

Accrued Expenses and Other Lo34

Accrued Expenses and Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities, excluding National, consisted of the following: March 31, December 31, ($ in thousands) 2017 2016 Accrued expenses: Professional fees $ 1,450 $ 1,253 Salaries, bonuses and related benefits 3,532 2,846 Accrued Severance - 53 Ovamed manufacturing rights – short term component 900 900 Research and development 680 394 Dr. Falk Pharma milestone 2,684 2,634 Other 1,874 2,002 Total accrued expenses $ 11,120 $ 10,082 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 5,020 5,014 Total other long-term liabilities $ 5,020 $ 5,014
National Holdings Corporation [Member]
Components of Accrued Expenses and Other Long-Term Liabilities	National’s accounts payable and other accrued expenses as of December 31, 2016, consisted of the following: December 31, 2016 Legal $ 752 Audit 263 Telecommunications 178 Data Services 235 Regulatory 623 Settlements 421 Deferred rent 123 Contingent consideration payable 623 Other 1,995 Total $ 5,213

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	3 Months Ended
	Mar. 31, 2017
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities are as follows: As of March 31, 2017 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation Caelum National Holdings Total NCI equity share $ (842) $ (236) $ 46,581 $ 21,009 $ (543) $ (1,684) $ (153) $ (3) $ 17,022 $ 81,151 Net loss attributed to non-controlling interests (68) (4) (1,674) (2,734) (68) (323) (54) (145) 2,490 (2,580) Non-controlling interests in consolidated entities $ (910) $ (240) $ 44,907 $ 18,275 $ (611) $ (2,007) $ (207) $ (148) $ 19,512 $ 78,571 As of December 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Cellvation National Holdings Total NCI equity share $ (494) $ (217) $ 12,376 $ 32,160 $ (192) $ (612) $ 4 $ 17,643 $ 60,668 Net loss attributed to non-controlling interests (349) (19) (1,805) (11,733) (355) (1,155) (158) (621) (16,195) Non-controlling interests in consolidated entities $ (843) $ (236) $ 10,571 $ 20,427 $ (547) $ (1,767) $ (154) $ 17,022 $ 44,473
Components Of Non-Controlling Interests In Loss Of Consolidated Entities	The components of non-controlling interests in loss of consolidated entities are as follows: For the three months ended March 31, 2017 ($ in thousands) Avenue Coronado SO Mustang (2) Checkpoint (1) JMC Helocyte Cellvation Caelum National Holdings Total Non-controlling interests in loss of consolidated entities $ (68) $ (4) $ (1,674) $ (2,734) $ (68) $ (323) $ (54) $ (145) $ 2,490 $ (2,580) Non-controlling ownership 10.2 % 13.0 % 52.0 % 62.4 % 7.0 % 20.0 % 22.0 % 25.5 % 43.4 % (1) – Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights. (2) – Mustang is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights. For the three months ended March 31, 2016 ($ in thousands) Avenue Coronado SO Mustang Checkpoint JMC Helocyte Total Non-controlling interests in loss of consolidated entities $ (108) $ (5) $ (70) $ (4,037) $ (121) $ (97) $ (4,438) Non-controlling ownership 11.5 % 13.0 % 10.0 % 62.7 % 8.1 % 8.3 %

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the three months ended March 31, 2017 and 2016: For the Three Months Ended March 31, 2017 2016 Warrants to purchase Common Stock 383,453 544,835 Opus warrants to purchase Common Stock 1,860,000 - Options to purchase Common Stock 1,105,502 1,779,365 Unvested Restricted Stock 9,912,161 7,922,021 Unvested Restricted Stock Units 1,249,232 885,083 Total 14,510,348 11,131,304

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Activity	The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three months ended March 31, 2017 and 2016: For the Three Months Ended March 31, ($ in thousands) 2017 2016 Employee awards $ 1,830 $ 1,584 Non-employee awards 13 3 Fortress Companies (1) 1,086 1,279 Total stock-based compensation expense $ 2,929 $ 2,866 (1) Consists of approximately $ 5,000 1.0 46,000 47,000 8,000
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Weighted average Weighted Total weighted remaining average average intrinsic contractual life Number of shares exercise price value (years) Options vested and expected to vest at December 31, 2016 1,130,501 $ 3.73 $ 602,451 4.93 No activity - - - - Options vested and expected to vest at March 31, 2017 1,130,501 $ 3.73 $ 1,216,285 4.69 Options vested and exercisable 1,105,501 $ 3.71 $ 1,216,285 4.66
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress’s restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies (which is discussed below): Weighted average Number of shares grant price Unvested balance at December 31, 2016 10,094,095 $ 2.49 Restricted stock granted 1,325,396 2.70 Restricted stock vested (213,333) 2.75 Restricted stock units granted 215,000 3.61 Restricted stock units vested (41,250) 3.54 Unvested balance at March 31, 2017 11,379,908 $ 2.53
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Weighted average Total weighted remaining Weighted average average intrinsic contractual life Number of shares exercise price value (years) Outstanding as of December 31, 2016 2,263,453 $ 3.62 $ 79,800 4.74 Granted 167,946 3.37 - 4.96 Outstanding as of March 31, 2017 2,431,399 $ 3.60 $ 209,800 2.37 Exercisable as of March 31, 2017 471,399 $ 6.08 $ 139,800 1.98
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of options granted in 2017 was estimated using the following assumptions: March 31, 2017 Risk-free interest rate 1.93% - 2.22 % Expected dividend yield - % Expected term in years 5.38 - 6.98 % Expected volatility 103.98% - 105.95 %

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Schedule of Effective Date and Equity Fee Payble	The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidaries’ certificates of incorporation. PIK Dividend as a % of fully diluted outstanding Class of Stock Fortress Company Effective Date (1) capitalization Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock (1) – Represents the effective date of each subsidiary’s Founders Agreement. While certain Founders Agreements may have been amended and restated subsequently, as described in the Company’s Form 10-K for the year ended December 31, 2016 filed with the SEC on March 16, 2017, each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) – Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5
Schedule of The Effective Date and Annual Management Services agreement Fee Income Expense	The following table summarizes, by subsidiary, the effective date of the MSA and the annual consulting fee payable by the subsidiary to the Company in quarterly installments: ($ in thousands) Fortress Annual MSA Fee Company Effective Date R&D G&A (Income)/Expense Helocyte March 20, 2015 $ 250 $ 250 $ 500 Avenue February 17, 2015 250 250 500 Mustang March 13, 2015 250 250 500 Checkpoint March 17, 2015 250 250 500 Cellvation October 31, 2016 250 250 500 Caelum January 1, 2017 250 250 500 Cyprium March 13, 2017 250 250 500 Fortress (1,750) (1,750) (3,500) Consolidated (Income)/Expense $ - $ - $ -

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended March 31, 2017 Sales Development National Consolidated Net Revenue $ 2,085 $ 693 $ 41,904 $ 44,682 Direct cost of goods (469) - - (469) Sales and marketing costs (2,267) - - (2,267) Research and development - (8,404) - (8,404) General and administrative (319) (7,666) - (7,985) National Expenses - - (43,134) (43,134) Segment loss from operations $ (970) $ (15,377) $ (1,230) $ (17,577) Segment assets $ 4,039 $ 159,175 $ 48,697 $ 211,911

Organization and Description 40

Organization and Description of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 09, 2016	Mar. 31, 2017	Dec. 31, 2016	Apr. 27, 2016
Organization And Nature Of Business [Line Items]
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 0.001
National Holdings Corporation [Member]
Organization And Nature Of Business [Line Items]
Merger Agreement Minimum Percentage Of Shares In Tender Offer To Completed Merger	56.60%
Merger Agreement Termination Fee	$ 22.9
Common Stock Par Or Stated Value Per Share	$ 0.02			$ 0.02
Business Acquisition, Share Price	$ 3.25			$ 3.25

National Holdings Corporation -

National Holdings Corporation - Fair value of assets acquired and liabilities assumed at the date of the acquisition (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 27,498
Accounts receivable	4,889
Cash deposits with clearing organizations	1,030
Receivable from brokers, dealers and clearing agencies	1,607
Securities owned, at fair value	2,178
Prepaid expenses and other current assets	1,985
Property and equipment	1,132
Restricted cash	353
Goodwill	18,645	$ 18,645
Total assets	75,817
Liabilities
Accrued compensation payable	14,029
Accounts payable and accrued expenses	6,079
Deferred clearing and marketing credits	1,007
Warrants issuable	13,406
Other current liabilities	707
Total liabilities assumed	35,228
Non-controlling interests	17,717
Net assets acquired	22,872
Cash and cash equivalents from National	27,498
Cash to NHLD Shareholders (Tender Offer)	22,872
Net cash acquired in acquisition of National	4,626
Trademarks [Member]
Assets
Intangible assets	3,000
Customer Lists [Member]
Assets
Intangible assets	$ 13,500

National Holdings Corporation42

National Holdings Corporation - Amortization is calculated using the straight-line method over the estimated useful lives (Detail)	3 Months Ended
	Mar. 31, 2017
Trademarks [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Lists [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years

National Holdings Corporation43

National Holdings Corporation - gross carrying amounts related to acquired intangible assets (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Intangible assets at December 31, 2016	$ 15,991
Amortization expense	(408)
Intangible assets at March 31, 2017	$ 15,583

National Holdings Corporation44

National Holdings Corporation - future amortization of these intangible assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Total	$ 17,077	$ 17,408
National Holdings Corporation [Member]
Nine Months Ended December 31, 2017	1,242
Year Ended December 31, 2018	1,649
Year Ended December 31, 2019	1,649
Year Ended December 31, 2020	1,654
Year Ended December 31, 2021	1,649
Thereafter	7,740
Total	$ 15,583

National Holdings Corporation45

National Holdings Corporation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended
	Apr. 27, 2016	Mar. 31, 2017	Dec. 31, 2016	Sep. 09, 2016
Business Combination, Consideration Transferred		$ 22,872
Common Stock Par Or Stated Value Per Share		$ 0.001	$ 0.001
Goodwill		$ 18,645	$ 18,645
National Holdings Corporation [Member]
Business Acquisition, Percentage of Voting Interests Acquired	56.60%	56.60%		56.60%
Business Acquisition, Share Price	$ 3.25			$ 3.25
Number Of Shares Tendered	7
Business Combination, Consideration Transferred	$ 22,900
Common Stock Par Or Stated Value Per Share	$ 0.02			$ 0.02

Broker-Dealers and Clearing O46

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 2,858	$ 3,357
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		2,900
Allowance for Doubtful Accounts Receivable		600
Broker -Dealers And clearing Organisation [Member] | Other Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		$ 3,900

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail)	Mar. 31, 2017
Forgivable Loan Receivable [Member]
Debt Instrument, Interest Rate, Stated Percentage	9.00%

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 7,386	$ 7,376
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	6,777	6,657
Less: Accumulated depreciation	(621)	(445)
Property and equipment, net	6,156	6,212
Computer Equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 489	440
Useful Life (Years)	3 years
Furniture and Fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 887	821
Useful Life (Years)	5 years
Leasehold Improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 5,401	$ 5,396
Property, Plant and Equipment, Estimated Useful Lives	Various

Property and Equipment - Schedu

Property and Equipment - Schedule Of Interest Expenses For Debt Arrangements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, net	$ 7,376	$ 7,386
National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	1,364
Less: accumulated depreciation	(134)
Property and equipment, net	1,230
Equipment [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 719
Property Plant And Equipment Useful Life	5 years
Furniture And Fixtures [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 71
Property Plant And Equipment Useful Life	5 years
Leaseholds And Leasehold Improvements [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 298
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term of lease
Capital leases (primarily composed of computer equipment) [Member] | National Holdings [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 276
Property Plant And Equipment Useful Life	5 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 176,000	$ 4,000

Fair Value Measurements - Avenu

Fair Value Measurements - Avenue's Contingently Issuable Warrants with option pricing model (Detail) - Avenue [Member]	3 Months Ended
	Mar. 31, 2017
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.40%
Expected dividend yield	0.00%
Expected term in years	8 years 7 months 2 days
Expected volatility	83.00%
Probability of issuance of the warrant	50.00%

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		1.93%
Expected dividend yield		0.00%
Expected term in years		4 years 8 months 12 days
Expected volatility		98.23%
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%
Expected volatility	61.70%
Avenue [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.91%
Expected term in years	6 months
Avenue [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.21%
Expected term in years	1 year 9 months
Avenue [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.39%
Expected dividend yield	0.00%
Expected term in years	9 years 9 months 4 days
Expected volatility	86.00%
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%
Expected volatility	61.70%
Helocyte [Member] | Minimum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.91%
Expected term in years	6 months
Helocyte [Member] | Maximum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.189%
Expected term in years	1 year 7 months 28 days
Helocyte [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield	0.00%
Expected volatility	70.00%
Strike price	$ 0.44
Helocyte [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.769%
Expected term in years	4 years 3 months
Helocyte [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.859%
Expected term in years	4 years 8 months 1 day

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
National [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	$ 10,096	$ 14,359
Change in fair value		(4,263)
Fair value at end of period:		10,096
Avenue [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	200
Change in fair value	4
Fair value at end of period:	204	200
Avenue [Member] | Contingently Issuable Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	302
Change in fair value	(4)
Fair value at end of period:	298	302
Helocyte [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	167
Change in fair value	(75)
Fair value at end of period:	92	167
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	4,487
Change in fair value	93
Fair value at end of period:	$ 4,580	$ 4,487

Fair Value Measurements - Natio

Fair Value Measurements - National Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Assets
Long-term investments, at fair value	$ 746
Total	746
Liabilities
Liabilities	5,186
National Holdings Corporation [Member]
Assets
Total		$ 1,206
Liabilities
Liabilities		10,097
Contingently Issuable Warrant [Member]
Liabilities
Liabilities	298
Warrant [Member]
Liabilities
Liabilities	104
Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,580
Avenue Convertible Note [Member]
Liabilities
Liabilities	204
Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		172
Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		930
Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		104
Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		1
Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		10,096
Fair Value, Inputs, Level 1 [Member]
Assets
Long-term investments, at fair value	0
Total	0
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | National Holdings Corporation [Member]
Assets
Total		1,102
Liabilities
Liabilities		1
Fair Value, Inputs, Level 1 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		172
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		930
Fair Value, Inputs, Level 1 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		1
Fair Value, Inputs, Level 2 [Member]
Assets
Long-term investments, at fair value	0
Total	0
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | National Holdings Corporation [Member]
Assets
Total		104
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 2 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		104
Fair Value, Inputs, Level 2 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member]
Assets
Long-term investments, at fair value	746
Total	746
Liabilities
Liabilities	5,186
Fair Value, Inputs, Level 3 [Member] | National Holdings Corporation [Member]
Assets
Total		0
Liabilities
Liabilities		10,096
Fair Value, Inputs, Level 3 [Member] | Contingently Issuable Warrant [Member]
Liabilities
Liabilities	298
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Liabilities	104
Fair Value, Inputs, Level 3 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	4,580
Fair Value, Inputs, Level 3 [Member] | Avenue Convertible Note [Member]
Liabilities
Liabilities	$ 204
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0
Fair Value, Inputs, Level 3 [Member] | Corporate stock Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		$ 10,096

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 20,941
Change in fair value of investments	(668)
Change in fair value of convertible notes	97
Change in fair value of derivative liabilities	(4,342)
Balance	16,028
Contingently Issuable Warrant [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	14,661
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	(4,267)
Balance	10,394
Helocyte Convertible Note At Fair Value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	4,487
Change in fair value of investments	0
Change in fair value of convertible notes	93
Change in fair value of derivative liabilities	0
Balance	4,580
Avenue Convertible Note, at fair value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	200
Change in fair value of investments	0
Change in fair value of convertible notes	4
Change in fair value of derivative liabilities	0
Balance	204
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	179
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	(75)
Balance	104
Investment In Laser Device [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	250
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	0
Balance	250
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,164
Change in fair value of investments	(668)
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	0
Balance	$ 496

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended
	Sep. 30, 2016	Mar. 17, 2014	Mar. 31, 2017	Dec. 31, 2016	Dec. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments		$ 250,000	$ 300,000	$ 300,000
Equity Method Investment, Ownership Percentage		35.00%	56.60%
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total			$ 700,000
Investment Owned, at Fair Value			1,206,000	$ 2,357,000
Equity Securities Called by Warrant					$ 10,000
Origo Acquisition Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value			$ 500,000
Fair Value Assumptions Probability Of Business Combination			18.40%
Working Capital Note Convertible To Equity			$ 300,000
National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants	43.40%
Warrant Expiration Period	5 years
Percentage of outstanding shares, Tendered	80.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.25
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 5,400,000
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price			$ 0.11
Fair Value Assumptions, Expected Volatility Rate			0.18%
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price			$ 9.83
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares Received Under Purchase Agreement		$ 13,409,962
Percentage Of Shares Received Under Purchase Agreement		83.00%
Preferred Units, Issued		16,091,954

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 1,294	$ 83
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	400	0
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	83
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	575	0
Caelum Biosciences, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	219	0
Cyprium Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 100	$ 0

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($)	1 Months Ended					3 Months Ended
	Apr. 25, 2017	Mar. 31, 2017		Feb. 17, 2017	Jan. 31, 2017	Mar. 31, 2017		Mar. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						$ 1,294,000		$ 83,000
City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees				$ 100,000
Revenue Recognition Milestone Method Payments Due				100,000
Jubilant Biosys Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process		$ 400,000
Royalty Revenue		200,000				$ 500,000
National Institute of Child Health and Human Development [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Milestone Fees		$ 100,000
Columbia University [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Purchase of Assets					1,050,000
Shares Issued, Price Per Share		$ 0.028				$ 0.028
Stock Issued During Period, Value, Purchase of Assets						$ 29,000
Payment of Upfront Milestone Fees					$ 200,000
Revenue Recognition Milestone Method Payments Due					$ 5,500,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					10.00%
Collaborative Agreements with TGTX [Member] | NeuPharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Fees						28,000		17,000
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						$ 400,000		$ 0
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		62.40%	[1]			62.40%	[1]	62.70%
Checkpoint Therapeutics, Inc [Member] | Dana-Farber [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Purchase of Assets						$ 1,300,000
UCLA License [Member] | University of California [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment of Upfront Fees	$ 200,000
A&R CD123 License [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method Payments Due				14,500,000
A&R IL-13 License [Member] | City Of Hope [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process						$ 300,000
Revenue Recognition Milestone Method Payments Due				$ 14,500,000
[1]	Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

Sponsored Research Agreements -

Sponsored Research Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 17, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Mar. 31, 2015
Research And Development Expense		$ 8,404,000
Checkpoint Therapeutics, Inc [Member]
Reimbursement Of Cost Recognized As Revenue		200,000	$ 300,000
Helocyte Inc [Member] | Pep Vax [Member]
Payments For Research And Development Expenses		200,000	1,000,000
Helocyte Inc [Member] | Triplex [Member]
Payments For Research And Development Expenses		500,000	$ 1,000,000
Mustang Bio, Inc [Member]
Research And Development Expense Payable Milestone Payment		500,000		$ 500,000	$ 2,000,000
City Of Hope [Member] | AR IL-13 License [Member]
Research And Development Expense		9,238
Payment of Upfront Milestone Fees	$ 9,238
Revenue Recognition Milestone Method Payments Due Over Three Years	200,000
Revenue Recognition Milestone Method Payments Due	100,000
City Of Hope [Member] | AR CD123 License [Member]
Research And Development Expense		$ 19,450
Payment of Upfront Milestone Fees	19,450
Revenue Recognition Milestone Method Payments Due Over Three Years	200,000
Revenue Recognition Milestone Method Payments Due	$ 100,000

Intangibles, net - Additional I

Intangibles, net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	$ 0	$ 200
Cost of Goods Sold, Amortization	133	0
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets	1,600
Cost of Goods Sold, Amortization	$ 100	$ 0

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Debt [Line Items]
Total notes payable, net	$ 35,575	$ 30,224
Less: Discount of notes payable	2,549	2,009
Total notes payable, net	33,026	28,215
IDB Note [Member]
Debt [Line Items]
Total notes payable, net	$ 14,929	14,929
Interest Rate	2.25%
Maturity Date	Feb - 2018
NSC Note [Member]
Debt [Line Items]
Total notes payable, net	$ 3,608	3,608
Interest Rate	8.00%
Maturity Date	Sep - 2018
Opus Credit Facility [Member]
Debt [Line Items]
Total notes payable, net	$ 9,000	7,000
Interest Rate	12.00%
Maturity Date	Sep - 2018
Helocyte Convertible Note One [Member]
Debt [Line Items]
Total notes payable, net	$ 1,054	1,031
Maturity Date	December 2,017
Helocyte Convertible Note One [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note One [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Avenue Convertible Note [Member]
Debt [Line Items]
Total notes payable, net	$ 204	200
Maturity Date	June - 2018
Avenue Convertible Note [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Avenue Convertible Note [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Two [Member]
Debt [Line Items]
Total notes payable, net	$ 2,093	2,051
Maturity Date	March - 2018
Helocyte Convertible Note Two [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note Two [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Three [Member]
Debt [Line Items]
Total notes payable, net	$ 1,011	991
Maturity Date	April - 2018
Helocyte Convertible Note Three [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note Three [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
2017 Subordinated Note Financing [Member]
Debt [Line Items]
Total notes payable, net	$ 3,254	0
Interest Rate	8.00%
Maturity Date	March - 2020
Helocyte Convertible Note four [Member]
Debt [Line Items]
Total notes payable, net	$ 422	$ 414
Maturity Date	May - 2018
Helocyte Convertible Note four [Member] | Minimum [Member]
Debt [Line Items]
Interest Rate	5.00%
Helocyte Convertible Note four [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt [Line Items]
Financing fee	$ 4	$ 0
Total Interest Expense and Financing Fee	698	620
LOC Fees [Member]
Debt [Line Items]
Interest	8	4
Interest and Debt Expense	8	4
IDB Note [Member]
Debt [Line Items]
Interest	82	80
Amortization of fees	0	1
Interest and Debt Expense	82	81
NSC Debt [Member]
Debt [Line Items]
Interest	71	167
Amortization of fees	38	368
Interest and Debt Expense	109	535
Opus Credit Facility [Member]
Debt [Line Items]
Interest	232	0
Amortization of fees	208	0
Interest and Debt Expense	440	0
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest	54	0
Financing fee	1	0
Interest and Debt Expense	55	0
Avenue Convertible Note [Member]
Debt [Line Items]
Financing fee	3	0
Interest and Debt Expense	3	0
D&O Insurance [Member]
Debt [Line Items]
Interest	1	0
Interest and Debt Expense	$ 1	$ 0

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Feb. 13, 2014
Debt [Line Items]
Debt discount recorded	$ 2,549,000	$ 2,009,000
Notes Payable	33,026,000	$ 28,215,000
Israel Discount Bank Of New York [Member]
Debt [Line Items]
Debt Instrument, Face Amount			$ 15,000,000
Notes Payable	14,900,000
Debt Instrument, Collateral Amount	15,000,000
Opus Credit Facility [Member]
Debt [Line Items]
Class Of Warrant Or Right Discount On Warrant	1,800,000
Warrants and Rights Outstanding	$ 9,000,000
NSC 2017 Note [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt discount recorded	$ 200,000
Debt Instrument, Face Amount	$ 3,250,000
Debt Instrument, Maturity Date, Description	Each Note is due on the third anniversary of its issuance, provided that the Company may extend the maturity date for two one-year periods in its sole discretion.
Paid-in-Kind Interest,Percentage	7.00%
Line of Credit Facility, Current Borrowing Capacity	$ 50,000,000
Percentage Of Placement Agent Fee	10.00%
Warrants on Sale Price of Note,Percentage	10.00%
Proceeds from Fees Received	$ 325,400
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	87,946
NSC 2017 Note [Member] | Minimum [Member]
Debt [Line Items]
Debt Instrument, Face Amount	$ 3,000,000
NSC 2017 Note [Member] | Maximum [Member]
Debt [Line Items]
Debt Instrument, Face Amount	$ 40,000,000

Accrued Expenses and Other Lo64

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued expenses:
Professional fees	$ 1,450	$ 1,253
Salaries, bonuses and related benefits	3,532	2,846
Accrued Severance	0	53
Ovamed manufacturing rights - short term component	900	900
Research and development	680	394
Dr. Falk Pharma milestone	2,684	2,634
Other	1,874	2,002
Total accrued expenses	11,120	10,082
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	5,020	5,014
Total other long-term liabilities	$ 5,020	$ 5,014

Accrued Expenses and Other Lo65

Accrued Expenses and Other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Legal	$ 1,450	$ 1,253
Other	1,874	2,002
Total	$ 24,864	23,871
National Holdings Corporation [Member]
Legal		752
Audit		263
Telecommunications		178
Data Services		235
Regulatory		623
Settlements		421
Deferred rent		123
Contingent consideration payable		623
Other		1,995
Total		$ 5,213

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2017		Mar. 31, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
NCI equity share	$ 81,151			$ 60,668
Net loss attributed to non-controlling interests	(2,580)		$ (4,438)	(16,195)
Non-controlling interests in consolidated entities	78,571			44,473
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(842)			(494)
Net loss attributed to non-controlling interests	(68)		(108)	(349)
Non-controlling interests in consolidated entities	(910)			(843)
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(236)			(217)
Net loss attributed to non-controlling interests	(4)		(5)	(19)
Non-controlling interests in consolidated entities	(240)			(236)
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	46,581			12,376
Net loss attributed to non-controlling interests	(1,674)	[1]	(70)	(1,805)
Non-controlling interests in consolidated entities	44,907			10,571
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	21,009			32,160
Net loss attributed to non-controlling interests	(2,734)	[2]	(4,037)	(11,733)
Non-controlling interests in consolidated entities	18,275			20,427
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(543)			(192)
Net loss attributed to non-controlling interests	(68)		(121)	(355)
Non-controlling interests in consolidated entities	(611)			(547)
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(1,684)			(612)
Net loss attributed to non-controlling interests	(323)		$ (97)	(1,155)
Non-controlling interests in consolidated entities	(2,007)			(1,767)
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(153)			4
Net loss attributed to non-controlling interests	(54)			(158)
Non-controlling interests in consolidated entities	(207)			(154)
Caelum [Member]
Noncontrolling Interest [Line Items]
NCI equity share	(3)
Net loss attributed to non-controlling interests	(145)
Non-controlling interests in consolidated entities	(148)
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share	17,022			17,643
Net loss attributed to non-controlling interests	2,490			(621)
Non-controlling interests in consolidated entities	$ 19,512			$ 17,022
[1]	Mustang is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights.
[2]	Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

Non-Controlling Interests - S67

Non-Controlling Interests - Summary Of Components of Non-Controlling Interests in Loss of Consolidated Entities (Detail) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2017		Mar. 31, 2016	Dec. 31, 2016
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (2,580)		$ (4,438)	$ (16,195)
Avenue [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (68)		$ (108)	(349)
Non-controlling ownership	10.20%		11.50%
Coronado SO Co, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (4)		$ (5)	(19)
Non-controlling ownership	13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (1,674)	[1]	$ (70)	(1,805)
Non-controlling ownership	52.00%	[1]	10.00%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (2,734)	[2]	$ (4,037)	(11,733)
Non-controlling ownership	62.40%	[2]	62.70%
JMC [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (68)		$ (121)	(355)
Non-controlling ownership	7.00%		8.10%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (323)		$ (97)	(1,155)
Non-controlling ownership	20.00%		8.30%
Cellvation [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (54)			(158)
Non-controlling ownership	22.00%
National Holdings [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ 2,490			$ (621)
Non-controlling ownership	43.40%
Caelum [Member]
Noncontrolling Interest [Line Items]
Non-controlling interests in loss of consolidated entities	$ (145)
Non-controlling ownership	25.50%
[1]	Mustang is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Mustang’s Class A preferred shares which provide super-majority voting rights.
[2]	Checkpoint is consolidated with Fortress’s operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A common shares which provide for super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	14,510,348	11,131,304
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	383,453	544,835
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,860,000	0
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,105,502	1,779,365
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	9,912,161	7,922,021
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,249,232	885,083

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 2,929	$ 2,866
Fortress Companies [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	[1]	1,086	1,279
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		1,830	1,584
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 13	$ 3
[1]	Consists of approximately $5,000 of Avenue's compensation expenses, approximately $1.0 million of Checkpoint's compensation expenses, approximately $46,000 of JMC's compensation expenses, approximately $47,000 of Helocyte's compensation expenses and approximately $8,000 of Cellvation's compensation expenses on equity grants for the three months ended March 31, 2017.

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options vested and expected to vest	1,130,501
Number of shares, Options vested and expected to vest	1,130,501	1,130,501
Number of shares, Options vested and exercisable	1,105,501
Weighted average exercise price, Options vested and expected to vest	$ 3.73
Weighted average exercise price, Options vested and expected to vest	3.73	$ 3.73
Weighted average exercise price, Options vested and exercisable	$ 3.71
Total Weighted average intrinsic value, Options vested and expected to vest	$ 602,451
Total Weighted average intrinsic value, Options vested and expected to vest	1,216,285	$ 602,451
Total weighted average intrinsic value, Options vested and exercisable	$ 1,216,285
Weighted average remaining contractual life (years), Options vested and expected to vest	4 years 8 months 8 days	4 years 11 months 5 days
Weighted average remaining contractual life (years), Options vested and exercisable	4 years 7 months 28 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance | shares	10,094,095
Number of shares, Restricted stock granted | shares	1,325,396
Number of shares, Restricted stock vested | shares	(213,333)
Number of shares, Restricted stock units granted | shares	215,000
Number of shares, Restricted stock units vested | shares	(41,250)
Number of shares, Unvested balance | shares	11,379,908
Weighted average grant price, Unvested balance | $ / shares	$ 2.49
Weighted average grant price, Restricted stock granted | $ / shares	2.70
Weighted average grant price, Restricted stock vested | $ / shares	2.75
Weighted average grant price, Restricted stock units granted | $ / shares	3.61
Weighted average grant price, Restricted stock units vested | $ / shares	3.54
Weighted average grant price, Unvested balance | $ / shares	$ 2.53

Stockholders' Equity - Summariz

Stockholders' Equity - Summarizes Fortress warrant activities (Detail) - Warrant [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding	2,263,453
Number of shares, Granted	167,946
Number of shares, Outstanding	2,431,399	2,263,453
Number of shares, Exercisable	471,399
Weighted average exercise price, Outstanding	$ 3.62
Weighted average exercise price, Granted	3.37
Weighted average exercise price, Outstanding	3.6	$ 3.62
Weighted average exercise price, Exercisable	$ 6.08
Total weighted average instrinsic value, Outstanding	$ 79,800
Total weighted average intrinsic value, Granted	0
Total weighted average intrinsic value, Cancelled	209,800
Total weighted average intrinsic value, Exercisable	$ 139,800
Weighted average remaining contractual life (years), Outstanding	2 years 4 months 13 days	4 years 8 months 26 days
Weighted average remaining contractual life, Granted (years)	4 years 11 months 16 days
Weighted average remaining contractual life, Exercisable (years)	1 year 11 months 23 days

Stockholders' Equity - Fair val

Stockholders' Equity - Fair value of options (Detail)	3 Months Ended
	Mar. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, Minimum	1.93%
Risk-free interest rate, Maximum	2.22%
Expected dividend yield	0.00%
Expected volatility, Minimum	103.98%
Expected volatility, Maximum	105.95%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	5 years 4 months 17 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term in years	6 years 11 months 23 days

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Sep. 09, 2016	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period			85.00%
Employee Stock Purchase Plan to eligible employees, compensation expense recognized			$ 35,000	$ 27,000
Research And Development Expense			8,404,000
General and Administrative Expense			7,985,000
Share-based Compensation			$ 2,929,000	2,866,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Warrants Issued		853,677
Percentage Of Shares Issued To Placement Agent			10.00%
Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			8 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 1,500,000
Capital Units, Authorized		100,000,000
Share-based Compensation			$ 100,000
Dr. Rosenwald [Member] | Longterm Incentive Program [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		552,698
Mustang [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from Issuance of Private Placement		$ 8,536,774
Mustang [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8.50
Stock Issued During Period, Value of Warrants Excercised			$ 65,000
Avenue Therapeutics, Inc. [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research And Development Expense			2,000	5,000
General and Administrative Expense			2,000	5,000
Allocated Share-based Compensation Expense			$ 5,000	9,000
Mustang Bio, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate Number of Shares of Common Stock,Percentage			2.50%
Stock Issuance Costs			$ 1,200,000
Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Issued During Period Shares warrants Exercised			2,500
Journey Medical Corporation [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			290,000
Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and Administrative Expense			$ 100,000
Allocated Share-based Compensation Expense			1,000,000	1,100,000
Share-based Compensation			400,000	800,000
JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense			46,000	200,000
Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense			47,000
Helocyte Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 month 6 days
Share-based Compensation			37,000	62	$ 62,000
Cellvation Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense			8,000
Cellvation Inc [Member] | Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation			5,000	0
Cellvation Inc [Member] | Non-employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation			$ 3,000	0
National Holdings Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 3.25
National Holdings Corporation [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee	10.00%
Proceeds from Issuance of Private Placement		$ 55,500,000
Warrants Issued		2,134,193
Private Placement Stock Units Shares To Be Issued			10,000
Percentage Of Shares Issued To Placement Agent		10.00%
National Holdings Corporation [Member] | Mustang Bio, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from Issuance of Private Placement			$ 64,000
Warrants Issued			6,400
Payments of Stock Issuance Costs			$ 5,500,000
National Holdings Corporation [Member] | Mustang Bio, Inc [Member] | Private Placement [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage Of Placement Agent Fee			10.00%
Proceeds from Issuance of Private Placement			$ 400,000
Warrants Issued			16,000
Payments of Stock Issuance Costs			$ 42,000
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense			800,000	1,300,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense			2,100,000	1,600,000
General and Administrative Expense [Member] | Helocyte Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation			$ 10,000	500
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			3,400,000
Share-based Compensation			$ 38,000	100,000
Restricted Stock [Member] | Checkpoint Therapeutics, Inc [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation			500,000	300,000
Restricted Stock [Member] | JMC [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation			$ 8,000	$ 35,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			3 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized			800,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common Stock issued in connection with the first ESPP offering			177,919
Common Stock, Capital Shares Reserved for Future Issuance			22,081
Employee Stock Option [Member] | Journey Medical Corporation [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%

Related Party Transactions - Sc

Related Party Transactions - Schedule of Effective Date and Equity Fee Payble (Detail)	3 Months Ended
	Mar. 31, 2017
Helocyte Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 20, 2015	[1]
Avenue Therapeutics, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Feb. 17, 2015	[1]
Mustang Bio, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2015	[1]
Checkpoint Therapeutics, Inc [Member]
Dividends, Paid-in-kind,Percentage	0.00%	[2]
Dividends Payable, Date Declared	Mar. 17, 2015	[1]
Cellvation Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Oct. 31, 2016	[1]
Caelum Biosciences, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Jan. 1, 2017	[1]
Cyprium Biosciences, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2017	[1]
[1]	Represents the effective date of each subsidiary’s Founders Agreement. While certain Founders Agreements may have been amended and restated subsequently, as described in the Company’s Form 10-K for the year ended December 31, 2016 filed with the SEC on March 16, 2017, each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2]	Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.

Related Party Transactions - 76

Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Annual Management Services Agreement Fee Income Expense	$ 0
Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	0
Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	0
Helocyte Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 20, 2015
Helocyte Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Helocyte Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Avenue Therapeutics, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Feb. 17, 2015
Avenue Therapeutics, Inc. [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Avenue Therapeutics, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Mustang Bio, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2015
Mustang Bio, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Mustang Bio, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Checkpoint Therapeutics, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 17, 2015
Checkpoint Therapeutics, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Checkpoint Therapeutics, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Cellvation Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Oct. 31, 2016
Cellvation Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Cellvation Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Caelum Biosciences, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Jan. 1, 2017
Caelum Biosciences, Inc. [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Caelum Biosciences, Inc. [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Cyprium Biosciences, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2017
Cyprium Biosciences, Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	$ 250
Cyprium Biosciences, Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	250
Fortress Biotech Inc [Member]
Annual Management Services Agreement Fee Income Expense	(3,500)
Fortress Biotech Inc [Member] | Research and Development Expense [Member]
Annual Management Services Agreement Fee Income Expense	(1,750)
Fortress Biotech Inc [Member] | Selling, General and Administrative Expenses [Member]
Annual Management Services Agreement Fee Income Expense	$ (1,750)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2015	Mar. 31, 2017	Mar. 31, 2016	Sep. 09, 2016	Apr. 27, 2016	Mar. 17, 2014
Related Party Transaction [Line Items]
Lease Sharing Agreements Contributions To Property Under Lease		$ 100,000
Equity Method Investment, Ownership Percentage		56.60%				35.00%
National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		56.60%		56.60%	56.60%
NSC 2017 Note [Member]
Related Party Transaction [Line Items]
Proceeds from Fees Received		$ 325,400
Percentage Of Placement Agent Fee		10.00%
Warrants on Sale Price of Note,Percentage		10.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		87,946
Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 10,000
Board of Directors Chairman [Member] | National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		4.60%
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Payments for Rent		$ 300,000
Due from Related Parties, Current		$ 54,000
Checkpoint [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired		2.50%
Checkpoint [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 28,000
OPPM [Member]
Related Party Transaction [Line Items]
Payments for Rent		57,000
Due from Related Parties, Current		12,000
Mustang [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	7,500
Avenue [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 5,000
Desk Share Agreements [Member]
Related Party Transaction [Line Items]
Payments for Rent		600,000
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement		$ 200,000	$ 100,000

Net Capital Requirements of B78

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail)	Dec. 31, 2016USD ($)
Minimum [Member]
Ratio of Indebtedness to Net Capital	1
Maximum [Member]
Ratio of Indebtedness to Net Capital	15
National Securities [Member]
Net Capital	$ 8,562,434
Excess Net Capital at 1000 Percent	8,312,434
Minimum Net Capital Required for Broker-Dealer Subsidiary	250,000
Vfinance Investments [Member]
Net Capital	2,319,352
Excess Net Capital at 1000 Percent	1,319,352
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000
Vfinance Investments [Member] | Minimum [Member]
Ratio of Indebtedness to Net Capital	0.7
Vfinance Investments [Member] | Maximum [Member]
Ratio of Indebtedness to Net Capital	1

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Net Revenue	$ 44,682
Direct cost of goods	(469)
Sales and marketing costs	(2,267)
Research and development	(8,404)
General and administrative	(7,985)
National Expenses	62,259	$ 15,751
Segment loss from operations	(17,577)	$ (15,091)
Segment assets	211,911		$ 170,731
Dermatology Products Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue	2,085
Direct cost of goods	(469)
Sales and marketing costs	(2,267)
Research and development	0
General and administrative	(319)
National Expenses	0
Segment loss from operations	(970)
Segment assets	4,039
Pharmaceutical And Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue	693
Direct cost of goods	0
Sales and marketing costs	0
Research and development	(8,404)
General and administrative	(7,666)
National Expenses	0
Segment loss from operations	(15,377)
Segment assets	159,175
National [Member]
Segment Reporting Information [Line Items]
Net Revenue	41,904
Direct cost of goods	0
Sales and marketing costs	0
Research and development	0
General and administrative	0
National Expenses	(43,134)
Segment loss from operations	(1,230)
Segment assets	$ 48,697

Segment Information - Additiona

Segment Information - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Customer One [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	$ 0.8
Accounts Receivable, Net	0.5
Customer Two [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Gross	0.8	$ 1.1
Accounts Receivable, Net	$ 0.5	$ 0.5

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - Subordinated Note 2017 [Member] $ / shares in Units, $ in Thousands	May 01, 2017USD ($)$ / sharesshares
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 8,550
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	234,438
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.65
Payments of Debt Issuance Costs	$ 900